(Circulation. 2001;104:2797.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From Cardiac Ultrasound, Massachusetts General Hospital, 55 Fruit St, Boston, Mass.
Correspondence to Arthur E. Weyman, Cardiac Ultrasound Laboratory, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114-2241. E-mail aeweyman{at}partners.org
| Abstract |
|---|
|
|
|---|
Methods and Results A normal TTE was based on normal cardiac structure and function during complete Doppler TTE studies. The PASP was calculated by use of the modified Bernoulli equation, with right atrial pressure assumed to be 10 mm Hg. Among TTE normal subjects, 3790 subjects (2432 women, 1358 men) from 1 to 89 years old had a measured PASP. The mean PASP was 28.3±4.9 mm Hg (range 15 to 57 mm Hg). PASP was independently associated with age, body mass index (BMI), male sex, left ventricular posterior wall thickness, and left ventricular ejection fraction (P<0.001). The estimated upper 95% limit for PASP among lower-risk subjects was 37.2 mm Hg. A PASP >40 mm Hg was found in 6% of those >50 years old and 5% of those with a BMI >30 kg/m2.
Conclusions Among 3790 echocardiographically normal subjects, PASP was associated with age, BMI, sex, wall thickness, and ejection fraction. Of these subjects, 28% had a PASP >30 mm Hg, and the expected upper limit of PASP may include 40 mm Hg in older or obese subjects. These findings support the use of age- and BMI-corrected values in establishing the expected normal range for PASP.
Key Words: hypertension, pulmonary obesity aging sex echocardiography
| Introduction |
|---|
|
|
|---|
Transthoracic echocardiography (TTE) has been validated for the noninvasive assessment of cardiac structure and function in clinical and population studies.7 In individual subjects, estimation of right ventricular systolic pressure (RVSP) by Doppler TTE assessment of tricuspid valve regurgitation (TR) jet peak velocity accurately predicts the PASP observed by invasive measurement.810 It has been suggested, however, that Doppler TTE methods may overestimate PASP in population studies, because TR is more common and more easily recorded in patients with higher PASP.9
To evaluate the factors influencing observed PASP, we studied the clinical and echocardiographic correlates and range of PASP in echocardiographically normal subjects ("echocardiographic normals") derived from a large clinical database. We examined trends in the detection of TR and the measurement of PASP and assessed their impact on observed PASP.
| Methods |
|---|
|
|
|---|
TR was graded as none, trace, mild, moderate, or severe by assessment of the color-flow jet in relation to the RA area in multiple orthogonal views.13 Only subjects with less than moderate TR were considered for this analysis. With continuous-wave Doppler, the maximum peak TR velocity (V) recorded from any view was used to determine the RVSP with the simplified Bernoulli equation (RVSP=4V2+RAP), with RA pressure (RAP) assumed to be 10 mm Hg. PASP was assumed to equate the RVSP in the absence of pulmonic stenosis and RV outflow tract obstruction. Reports were not excluded on the basis of the PASP values recorded unless
1 criteria for normality were not met. All studies were interpreted by a clinical staff member experienced in TTE (level III, American Society of Echocardiography).
Demographic data and the indication for the TTE study were collected. Reports for subjects <1 year old were excluded because of the variability of PA pressures during early infancy. The indications for the TTE study are shown in Table 1. These indications were determined from the clinical echocardiography request forms and represent the question raised to initiate referral for Doppler TTE. It is important to note that many of the suspected conditions were excluded by a normal TTE (eg, a subject referred with the question of "assess murmur" who had a normal Doppler echo study can be considered normal).
|
Statistical Analysis
Results are expressed as mean±SD. Spearman rank correlations were used to test the association of continuous variables with mean PASP. Mean PASPs between groups were compared by ANOVA, and intergroup differences were assessed by multiple-range testing. The referral category "assess murmur" was used as the reference group for comparison of mean PASP. Multiple linear regression analysis was used to determine the slope of the association between PASP and continuous variables. Frequency data with proportions were compared by the
2 test. Multiple logistic regression with forward stepwise selection (Wald) was used to test the independent relation between nominal independent variables and a PASP >30 mm Hg. Subjects from referral categories potentially at higher risk of pulmonary hypertension (n=578; see Table 3) were excluded for the reference range estimates. Reference intervals are based on the estimated central 95% values (mean±1.96xSD). Statistical significance was taken as a 2-sided P value of <0.05. Analysis was performed with SAS 6.12 statistical software (SAS Institute).
|
| Results |
|---|
|
|
|---|
|
Detection of TR and PASP Recording
Overall, less than moderate TR was detected in 69% (n=10 719) of those with a normal TTE. Detection of less than moderate TR increased progressively from 48% (631/1303) of subjects with a normal TTE in 1990 to 80% (1573/1965) of normals in 1999 (P<0.001). Similarly, PASP recording increasing progressively from 9% (57/631) of those with trace or mild TR in 1990 to 59% (926/1573) in 1999 (P<0.001). Despite this increased sensitivity for the detection of TR and the recording of a PASP, the annual mean PASP remained relatively constant (range of means, 27.1 to 29.0 mm Hg). The mean absolute difference in PASP between years was 0.5 mm Hg (range, 0 to 1.9 mm Hg). After adjustment for age and sex, there was no difference in the annual mean PASP over the last 5 years of observation.
Correlates of PASP and Predictors of Elevated PASP
On bivariate analyses, PASP was associated with age (Spearman
[rs]=0.25), BMI (rs=0.19), interventricular septal (rs=0.18) and posterior wall (rs=0.18) thickness, aortic (rs=0.13) and LA (rs=0.11) diameter, and EF (rs=0.06) (all P<0.001). After adjustment for age and BMI, men had higher PASP than women (adjusted mean PASP, 28.8 versus 28.0 mm Hg, respectively; P<0.001). The Figure demonstrates the mean PASP across age (A) and BMI (B) groups for each sex.
|
On multiple linear regression analyses, age, BMI, male sex, EF, posterior wall thickness, and clinical referral category composed the best predictive model for PASP (model R2=0.12, P<0.001). Similar factors composed the best-fit models for PASP among analyses restricted to women (excluding sex as a variable) (R2=0.17, P<0.001), subjects >20 years old (R2=0.14, P<0.001), and those at lower risk of pulmonary hypertension (R2=0.12, P<0.001).
The mean PASPs for each referral category, adjusted for age, sex, and BMI, are shown in Table 3. General linear model analysis indicated a significant overall association between referral category and mean PASP (P<0.001). The highest observed mean PASP was among subjects with a history of suspected or known pulmonary hypertension, pulmonary embolism, or RV dysfunction (30.6±6.8 mm Hg). With reference to the index category ("assess murmur"), the 4 highest PASP categories were found to have higher mean PASPs (Table 3).
Among 3790 subjects with a recorded PASP, 1060 (28%) had a PASP >30 mm Hg. We used multiple logistic regression to determine the predictors of a PASP >30 mm Hg. We found age (>50 years) (OR 2.69; 95% CI 2.24, 3.23), BMI (>30 kg/m2) (OR 1.67; 95% CI 1.34, 2.07), LV posterior wall thickness (>9 mm) (OR 1.54; 95% CI, 1.30, 1.82), and male sex (OR 1.27; 95% CI 1.09, 1.48) to be independent predictors of a higher PASP (all P<0.01).
PASP Reference Range
Among all subjects with a recorded PASP (n=3790), the mean PASP was 28.3±4.9 mm Hg (95% CI 18.7, 37.9 mm Hg). This 95% upper limit is equivalent to a peak TR velocity of 2.64 m/s. After exclusion of subjects referred for TTE because of the suspicion of clinical conditions that may be associated with pulmonary hypertension (n=578; see Table 3), the mean PASP in the remaining subjects (n=3212) was 28.0±4.7 mm Hg (95% CI 18.8, 37.2 mm Hg; peak TR velocity 2.61 m/s). Among these lower-risk subjects, we also defined age- and BMI-specific 95% reference ranges for PASP in women and men (Table 4).
|
| Discussion |
|---|
|
|
|---|
Detection of TR and Recording of PASP
The estimation of PASP by Doppler techniques requires a detectable TR jet. Early Doppler TTE studies suggested that the proportion of patients with recordable TR increased with increasing PA pressure and that TR was difficult to record in normals.9 Because of this tendency to undersample regurgitant lesions in patients with lower PA pressures, it has been suggested that Doppler TTE tends to systematically overestimate PA pressures in population studies. In our study, the percentage of echocardiographic normals in whom less than moderate TR could be detected increased from 48% in 1990 to 80% in 1999. Because it is unlikely that the actual prevalence of trace or mild TR has increased, we attribute this change to improvements in instrumentation and recording techniques. Interestingly, the mean PASP has not changed significantly from the beginning to the end of our study, despite the increase in the percentage of "normals" in whom these values were recorded. If there had been a systematic bias in favor of higher PA pressures, one would have expected the mean PASP to decrease each year as the percentage of recordable trivial and mild TR increased, which was not the case. Formal assessment of the reproducibility for measurements of peak TR velocity in our database was not undertaken. A lower reproducibility may be expected for clinical studies compared with research trials, which would be expected to increase the range of observed PASP values.
Referral Categories and PASP
Attempts to define normal values for PA pressure have proven difficult, and many strategies have been used. Studies of selected normals or control groups for other echocardiographic studies are generally small and nonrandomized and therefore suffer from potential selection bias and fail to provide the power to reveal many of the associations demonstrated in this article. The commonly used reference values for PA pressure are derived from catheterization normals. Although similar in concept to the use of echocardiographic normals as a reference group, patients referred for catheterization are likely to be more selected than those referred for echocardiography.
Our reference normal group (assess murmur; n=1414; 37% of the total) is consistent with the populations represented in most studies of echocardiographic normals in which patients with suspected confounding diseases are excluded a priori. The mean PASP for this group was 28.1 mm Hg. The grand mean for all subjects (28.3 mm Hg) and the mean after exclusion of groups with PASP values significantly higher than the reference group (27.9 mm Hg) differ from the reference mean by only 0.2 mm Hg, which is well below the accuracy of clinical measurement.
Similar values for PASP have been observed in previous studies based on echocardiographic normals. In a study of 53 subjects 14 to 55 years old who were screened for cardiac and pulmonary disease, Aessopos et al14 reported a mean RV-to-RA gradient of 19.3 mm Hg (equivalent to a PASP of 29.3 mm Hg if RA pressure is assumed to be 10 mm Hg). Dib et al3 found a mean PASP of 26.6 mm Hg among 134 subjects 20 to 85 years old. In young, highly conditioned athletes, an average peak TR velocity of 2.25 m/s (equivalent to a PASP of 30.2 mm Hg) has been reported.15 Thus, our mean values approximate the midpoint of other smaller studies. Because our subjects were not formally screened for the presence of conditions known to be associated with elevated PA pressure, the inclusion of subjects with such conditions would tend to increase the observed mean PASP, and the present study should be interpreted in this context.
Correlates of PASP
This study has demonstrated an independent association of age, male sex, and BMI with PASP among echocardiographic normals. Age was the strongest predictor of PASP, with an average increase in PASP of 0.8 mm Hg per decade over the wide age range studied. Previous studies in small groups of patients have also reported an association between age and PASP.13 Although there is variability between studies, there is an increase in PASP of
1 mm Hg per decade of age among echocardiographic normals. This has been attributed to an increase in pulmonary vascular resistance and decreased LV compliance with aging.
We also noted that after adjustment for age, PASPs were significantly higher in men than in women. This finding differs from most previous reports and may relate to the large numbers in our study and the fact that we have corrected these values for differences in age between the sex groups. Of the echocardiographic parameters, LV posterior wall and interventricular septal thickness were independently associated with PASP even within the normal range of wall thickness considered in this study, a relationship not previously appreciated. LV wall thickness may relate to PASP through diastolic dysfunction and the effects of decreased LV compliance and increased LV end-diastolic pressure with aging and in such conditions as systemic hypertension.16
Although LV dysfunction is associated with pulmonary hypertension in a variety of cardiac diseases, we observed a positive association between LV EF and PASP within the normal range of EF (ie, as the EF increased, the PASP increased). LV EF also correlated directly with LA size and LV end-diastolic internal diameter but remained predictive of PASP independent of these dimensions. The correlation of LVEF with LA and ventricular diameters suggests that the increase in EF may be mediated by the Frank-Starling mechanism. Increased EF and cardiac output (with higher pulmonary blood flow) may result in an increased PA pressure unless there is an accompanying decrease in pulmonary vascular resistance.15 Obesity is associated with an increased cardiac output, which may explain the association between BMI and PASP in this and other studies.4
Noninvasive Estimation of PASP
Doppler TTE has become the noninvasive method of choice in the estimation of PASP. A number of studies have found close correlation between Doppler-determined estimates by use of the peak TR jet velocity and simultaneous catheter-derived measures.8,10 To convert the RV-to-RA gradient to an absolute pressure, some estimate of RA pressure is required. Most commonly, a constant of 10 mm Hg is used, which has been shown to result in the most accurate prediction of PASP across the whole range of pressures encountered clinically. The constant 10 mm Hg, however, may overestimate RA pressure in patients with lower PA pressures and underestimate RA pressures in those with significantly elevated PA pressures. Other approaches, such as the use of a constant value of 5 mm Hg,15 reporting the transvalvular gradients instead of an absolute value for PASP,14 or the estimation of RA pressure from changes in inferior vena caval diameter during inspiration,17 have been used as alternatives. Because the 10 mm Hg value for RA pressure used in this study is a constant, individuals preferring to use other approaches may substitute different values for RA pressure without changing associations.
Comparison With Invasive Hemodynamic Data
The most widely used normal values for PA pressures are derived from catheterization studies.18 The upper limits for PA pressure in this and other studies of echocardiographic normals are often higher than those given from hemodynamic studies. This difference most likely relates to the constant used to estimate RA pressure and differences in the selection of subjects. Although values for normal PA pressure from catheterization studies are presented in standard textbooks of cardiology,11,18,19 these values are often not referenced, so analysis of the groups from which they are derived is difficult.
Data on the risks of systemic arterial hypertension and the benefits of blood pressure treatment are based predominantly on noninvasive measurement of arterial blood pressure. There are, however, sparse data on the potential risks associated with increasing PASP. PA pressure has been identified as a predictor of mortality in patients with primary pulmonary hypertension20 and subjects undergoing cardiac catheterization who had significant comorbid disease21 or dilated cardiomyopathy.22 These studies are of limited value to the assessment of morbidity and mortality associated with PA pressure in the general population. The widespread application of noninvasive Doppler TTE techniques for the assessment of PASP provides more meaningful data in less selected subjects and can ethically be applied to prospective community-based studies to determine whether there is an independent relationship between PA pressure and disease. From these studies, it may then be possible to establish whether there is a threshold of PA pressure above which adverse events are more likely or whether there is a graded risk of disease across the range of pressures encountered clinically. Pending such data, it seems reasonable to establish independent echo Doppler TTE reference ranges for PASP, because such values are likely to be the standard for future population studies.
Conclusions
This study represents the largest reported assessment of the clinical correlates of PASP. Detection of trivial or mild TR and measurement of PASP progressively improved during the past decade without an apparent impact on the observed mean PASP among echocardiographic normals. The ages and BMIs of subjects should be considered in the interpretation of their PASPs. We observed higher PASP in men than in women, independent of age and BMI. PASP correlated with LV wall thickness and EF, even within the normal range for these values. Among subjects with a normal Doppler TTE, 28% had a PASP >30 mm Hg. The expected upper limit of PASP is dependent on age, sex, and BMI and may include 40 mm Hg in some older or obese subjects.
| Acknowledgments |
|---|
Received May 17, 2001; revision received September 20, 2001; accepted September 28, 2001.
| References |
|---|
|
|
|---|
2. Abergel E, Chatellier G, Toussaint P, et al. Doppler-derived pulmonary arterial systolic pressure in patients with known systemic arterial pressures. Am J Cardiol. 1996; 77: 767769.[Medline] [Order article via Infotrieve]
3. Dib JC, Abergel E, Rovani C, et al. The age of the patient should be taken into account when interpreting Doppler assessed pulmonary artery pressures. J Am Soc Echocardiogr. 1997; 10: 7273.[Medline] [Order article via Infotrieve]
4.
de Divitiis O, Fazio S, Petitto M, et al. Obesity and cardiac function. Circulation. 1981; 64: 477482.
5.
Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 335: 609616.
6.
Rich S, Rubin L, Walker AM, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest. 2000; 117: 870874.
7.
Dai S, Ayres NA, Harrist RB, et al. Validity of echocardiographic measurement in an epidemiological study: project heart beat! Hypertension. 1999; 34: 236241.
8.
Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 1984; 70: 657626.
9. Berger M, Haimowitz A, Van Tosh A, et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985; 6: 359365.[Abstract]
10. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985; 6: 750756.[Abstract]
11. Weyman AE. Principles and Practice of Echocardiography. 2nd ed. Malvern, Pa: Lea & Febiger; 1982.
12. Nidorf SM, Picard MH, Triulzi MO, et al. New perspectives in the assessment of cardiac chamber dimensions during development and adulthood. J Am Coll Cardiol. 1992; 19: 983988.[Abstract]
13. Choong CY, Abascal VM, Weyman J, et al. Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J. 1989; 117: 636642.[Medline] [Order article via Infotrieve]
14. Aessopos A, Farmakis D, Taktikou H, et al. Doppler-determined peak systolic tricuspid pressure gradient in persons with normal pulmonary function and tricuspid regurgitation. J Am Soc Echocardiogr. 2000; 13: 645649.[Medline] [Order article via Infotrieve]
15.
Bossone E, Rubenfire M, Bach DS, et al. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol. 1999; 33: 16621666.
16.
Olivari MT, Fiorentini C, Polese A, et al. Pulmonary hemodynamics and right ventricular function in hypertension. Circulation. 1978; 57: 11851190.
17. Simonson JS, Schiller NB. Sonospirometry: a new method for noninvasive estimation of mean right atrial pressure based on two-dimensional echographic measurements of the inferior vena cava during measured inspiration. J Am Coll Cardiol. 1988; 11: 557564.[Abstract]
18. Skibo LK, Wexler L. Pulmonary angiography.In: Baim DS, Grossman W, eds. Cardiac Catheterization, Angiography, and Intervention. 5th ed. Baltimore, Md: Williams & Wilkins; 1991: 233253.
19. Rich S, Braunwald E, Grossman W. Pulmonary hypertension.In: Braunwald E, ed. A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia, Pa: WB Saunders; 1998: 780806.
20. DAlonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991; 115: 343349.
21.
Cooper R, Ghali J, Simmons BE, et al. Elevated pulmonary artery pressure: an independent predictor of mortality. Chest. 1991; 99: 112120.
22. Abramson SV, Burke JF, Kelly JJJr, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med. 1992; 116: 888895.
This article has been cited by other articles:
![]() |
The Task Force for the Diagnosis and Treatment of, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension Eur. Respir. J., December 1, 2009; 34(6): 1219 - 1263. [Full Text] [PDF] |
||||
![]() |
M. Bijl, H. Bootsma, and C. G. M. Kallenberg Pulmonary arterial hypertension in systemic lupus erythematosus: should we bother? Rheumatology, December 1, 2009; 48(12): 1471 - 1472. [Full Text] [PDF] |
||||
![]() |
J. A. Kline, M. T. Steuerwald, M. R. Marchick, J. Hernandez-Nino, and G. A. Rose Prospective Evaluation of Right Ventricular Function and Functional Status 6 Months After Acute Submassive Pulmonary Embolism: Frequency of Persistent or Subsequent Elevation in Estimated Pulmonary Artery Pressure Chest, November 1, 2009; 136(5): 1202 - 1210. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537. [Full Text] [PDF] |
||||
![]() |
B. D. Medoff, Y. Okamoto, P. Leyton, M. Weng, B. P. Sandall, M. J. Raher, S. Kihara, K. D. Bloch, P. Libby, and A. D. Luster Adiponectin Deficiency Increases Allergic Airway Inflammation and Pulmonary Vascular Remodeling Am. J. Respir. Cell Mol. Biol., October 1, 2009; 41(4): 397 - 406. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Yong, P. Khairy, P. De Guise, A. Dore, F. Marcotte, L.-A. Mercier, S. Noble, and R. Ibrahim Pulmonary Arterial Hypertension in Patients With Transcatheter Closure of Secundum Atrial Septal Defects: A Longitudinal Study Circ Cardiovasc Interv, October 1, 2009; 2(5): 455 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
J-L. Vachiery and G. Coghlan Screening for pulmonary arterial hypertension in systemic sclerosis Eur. Respir. Rev., September 1, 2009; 18(113): 162 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Mahjoub, F. Levy, M. Cassol, P. Meimoun, M. Peltier, D. Rusinaru, and C. Tribouilloy Effects of age on pulmonary artery systolic pressure at rest and during exercise in normal adults Eur J Echocardiogr, July 1, 2009; 10(5): 635 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R. J. Oudiz, et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S55 - S66. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gomberg-Maitland Something Subtle About Death: Isolated Systolic Pulmonary Pressure Circulation, May 26, 2009; 119(20): 2647 - 2649. [Full Text] [PDF] |
||||
![]() |
C. S.P. Lam, B. A. Borlaug, G. C. Kane, F. T. Enders, R. J. Rodeheffer, and M. M. Redfield Age-Associated Increases in Pulmonary Artery Systolic Pressure in the General Population Circulation, May 26, 2009; 119(20): 2663 - 2670. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Faoro, S. Boldingh, M. Moreels, S. Martinez, M. Lamotte, P. Unger, S. Brimioulle, S. Huez, and R. Naeije Bosentan Decreases Pulmonary Vascular Resistance and Improves Exercise Capacity in Acute Hypoxia Chest, May 1, 2009; 135(5): 1215 - 1222. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Grunig, S. Weissmann, N. Ehlken, A. Fijalkowska, C. Fischer, T. Fourme, N. Galie, A. Ghofrani, R. E. Harrison, S. Huez, et al. Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension: Results of a Multicenter European Analysis of Pulmonary Artery Pressure Response to Exercise and Hypoxia Circulation, April 7, 2009; 119(13): 1747 - 1757. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chemla, V. Castelain, S. Provencher, M. Humbert, G. Simonneau, and P. Herve Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults Chest, March 1, 2009; 135(3): 760 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maignan, M. Rivera-Ch, C. Privat, F. Leon-Velarde, J.-P. Richalet, and I. Pham Pulmonary Pressure and Cardiac Function in Chronic Mountain Sickness Patients Chest, February 1, 2009; 135(2): 499 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. McGoon and G. C. Kane Pulmonary Hypertension: Diagnosis and Management Mayo Clin. Proc., February 1, 2009; 84(2): 191 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Galiè and A. Manes CHAPTER 24 Pulmonary Hypertension ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Gladwin and E. Vichinsky Pulmonary Complications of Sickle Cell Disease N. Engl. J. Med., November 20, 2008; 359(21): 2254 - 2265. [Full Text] [PDF] |
||||
![]() |
T. Stuber, C. Sartori, C. S. Salmon, D. Hutter, S. Thalmann, P. Turini, P.-Y. Jayet, M. Schwab, C. Sartori-Cucchia, M. Villena, et al. Respiratory Nitric Oxide and Pulmonary Artery Pressure in Children of Aymara and European Ancestry at High Altitude Chest, November 1, 2008; 134(5): 996 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
O H Balint, A Samman, K Haberer, L Tobe, P McLaughlin, S C Siu, E Horlick, J Granton, and C K Silversides Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure Heart, September 1, 2008; 94(9): 1189 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bossone, R. Citro, W. F. Armstrong, and M. Rubenfire Latent Pulmonary Hypertension: Looking Beyond the Scene Chest, August 1, 2008; 134(2): 469 - 470. [Full Text] [PDF] |
||||
![]() |
N. Brechot, L. Gambotti, S. Lafitte, and R. Roudaut Usefulness of right ventricular isovolumic relaxation time in predicting systolic pulmonary artery pressure Eur J Echocardiogr, July 1, 2008; 9(4): 547 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Richalet, M. Rivera-Ch, M. Maignan, C. Privat, I. Pham, J.-L. Macarlupu, O. Petitjean, and F. Leon-Velarde Acetazolamide for Monge's Disease: Efficiency and Tolerance of 6-Month Treatment Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1370 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Gnecchi-Ruscone and F. Rigo Normal Range for Pulmonary Artery Systolic Pressure JAMA, May 7, 2008; 299(17): 2022 - 2022. [Full Text] [PDF] |
||||
![]() |
R. F. Machado, P. Y. Hsue, and C. F. Barnett Normal Range for Pulmonary Artery Systolic Pressure--Reply JAMA, May 7, 2008; 299(17): 2022 - 2023. [Full Text] [PDF] |
||||
![]() |
National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF] |
||||
![]() |
National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF] |
||||
![]() |
J. M. Golbin, V. K. Somers, and S. M. Caples Obstructive Sleep Apnea, Cardiovascular Disease, and Pulmonary Hypertension Proceedings of the ATS, February 15, 2008; 5(2): 200 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Kerr, O. C. Raffel, G. A. Whalley, I. Zeng, and R. A. Stewart Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation Eur. Heart J., February 1, 2008; 29(3): 363 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. I. Ataga, C. G. Moore, C. A. Hillery, S. Jones, H. C. Whinna, D. Strayhorn, C. Sohier, A. Hinderliter, L. V. Parise, and E. P. Orringer Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension Haematologica, January 1, 2008; 93(1): 20 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Vachiery and A. Pavelescu Exercise echocardiography in pulmonary hypertension Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H48 - H53. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cioffi, G. de Simone, G. Mureddu, L. Tarantini, and C. Stefenelli Right atrial size and function in patients with pulmonary hypertension associated with disorders of respiratory system or hypoxemia Eur J Echocardiogr, October 1, 2007; 8(5): 322 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Totaro and V. Argano Patient prosthesis mismatch after mitral valve replacement: Myth or reality? J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 697 - 701. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-K. Lam, V. Chan, P. Hendry, M. Ruel, R. Masters, P. Bedard, B. Goldstein, F. Rubens, and T. Mesana The impact of patient-prosthesis mismatch on late outcomes after mitral valve replacement J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1464 - 1473. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M Engelfriet, M. G J Duffels, T. Moller, E. Boersma, J. G P Tijssen, E. Thaulow, M. A Gatzoulis, and B. J M Mulder Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease Heart, June 1, 2007; 93(6): 682 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Levin, R. B. Buxton, J. P. Spiess, T. Arai, J. Balouch, and S. R. Hopkins Effects of age on pulmonary perfusion heterogeneity measured by magnetic resonance imaging J Appl Physiol, May 1, 2007; 102(5): 2064 - 2070. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dellegrottaglie, J. Sanz, M. Poon, J. F. Viles-Gonzalez, R. Sulica, M. Goyenechea, F. Macaluso, V. Fuster, and S. Rajagopalan Pulmonary Hypertension: Accuracy of Detection with Left Ventricular Septal-to-Free Wall Curvature Ratio Measured at Cardiac MR Radiology, April 1, 2007; 243(1): 63 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. McLean, I. Ting, S. J. Huang, and S. Wesley The use of the right ventricular diameter and tricuspid annular tissue Doppler velocity parameter to predict the presence of pulmonary hypertension Eur J Echocardiogr, March 1, 2007; 8(2): 128 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Collins, B. Bastian, L. Quiqueree, C. Jones, R. Morgan, and G. Reeves Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I) Eur J Echocardiogr, December 1, 2006; 7(6): 439 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Thorne, A. MacGregor, and C. Nelson-Piercy Risks of contraception and pregnancy in heart disease. Heart, October 1, 2006; 92(10): 1520 - 1525. [Full Text] [PDF] |
||||
![]() |
O. Distler and A. Pignone Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment Rheumatology, October 1, 2006; 45(suppl_4): iv22 - iv25. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-T. Ton-Nu, R. A. Levine, M. D. Handschumacher, D. J. Dorer, C. Yosefy, D. Fan, L. Hua, L. Jiang, and J. Hung Geometric Determinants of Functional Tricuspid Regurgitation: Insights From 3-Dimensional Echocardiography Circulation, July 11, 2006; 114(2): 143 - 149. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Becattini, G. Agnelli, R. Pesavento, M. Silingardi, R. Poggio, M. R. Taliani, and W. Ageno Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest, July 1, 2006; 130(1): 172 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Arias, F. Garcia-Rio, A. Alonso-Fernandez, I. Martinez, and J. Villamor Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: A randomized, controlled cross-over study Eur. Heart J., May 1, 2006; 27(9): 1106 - 1113. [Abstract] [Full Text] [PDF] |
||||
![]() |
G B Bleeker, P Steendijk, E R Holman, C-M Yu, O A Breithardt, T A M Kaandorp, M J Schalij, E E van der Wall, J J Bax, and P Nihoyannopoulos Acquired right ventricular dysfunction Heart, April 1, 2006; 92(suppl_1): i14 - i18. [Full Text] [PDF] |
||||
![]() |
I. Ben-Dor, M. R. Kramer, A. Raccah, Z. Iakobishvilli, D. Shitrit, G. Sahar, and D. Hasdai Echocardiography Versus Right-Sided Heart Catheterization Among Lung Transplantation Candidates Ann. Thorac. Surg., March 1, 2006; 81(3): 1056 - 1060. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cella, M. Saetta, S. Baraldo, G. Turato, A. Papi, G. Casoni, and M. Rigno Endothelial Cell Activity in Chronic Obstructive Pulmonary Disease Without Severe Pulmonary Hypertension Clinical and Applied Thrombosis/Hemostasis, October 1, 2005; 11(4): 435 - 440. [Abstract] [PDF] |
||||
![]() |
N Galie, A Manes, K V Farahani, F Pelino, M Palazzini, L Negro, S Romanazzi, and A Branzi Pulmonary arterial hypertension associated to connective tissue diseases Lupus, September 1, 2005; 14(9): 713 - 717. [Abstract] [PDF] |
||||
![]() |
G. Ramakrishna, J. Sprung, B. S. Ravi, K. Chandrasekaran, and M. D. McGoon Impact of Pulmonary Hypertension on the Outcomes of Noncardiac Surgery: Predictors of Perioperative Morbidity and Mortality J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1691 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Li, J. G. Dumesnil, P. Mathieu, and P. Pibarot Impact of valve prosthesis-patient mismatch on pulmonary arterial pressure after mitral valve replacement J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1034 - 1040. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dehnert, E. Grunig, D. Mereles, N. von Lennep, and P. Bartsch Identification of individuals susceptible to high-altitude pulmonary oedema at low altitude Eur. Respir. J., March 1, 2005; 25(3): 545 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hesselstrand, R. Ekman, J. Eskilsson, A. Isaksson, A. Scheja, A.-K. Ohlin, and A. Akesson Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001 Rheumatology, March 1, 2005; 44(3): 366 - 371. [Abstract] [Full Text] [PDF] |
||||
![]() |
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF] |
||||
![]() |
D. Chemla, V. Castelain, M. Humbert, J.-L. Hebert, G. Simonneau, Y. Lecarpentier, and P. Herve New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure Chest, October 1, 2004; 126(4): 1313 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Homma, M. R. DiTullio, R. L. Sacco, R. R. Sciacca, J.P. Mohr, and for PICSS Investigators Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients With Patent Foramen Ovale Stroke, September 1, 2004; 35(9): 2145 - 2149. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Rubin and R. Naeije Sildenafil for Enhanced Performance at High Altitude? Ann Intern Med, August 3, 2004; 141(3): 233 - 235. [Full Text] [PDF] |
||||
![]() |
R. J. Barst, M. McGoon, A. Torbicki, O. Sitbon, M. J. Krowka, H. Olschewski, and S. Gaine Diagnosis and differential assessment of pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 40S - 47S. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Schachna, F. M. Wigley, B. Chang, B. White, R. A. Wise, and A. C. Gelber Age and Risk of Pulmonary Arterial Hypertension in Scleroderma Chest, December 1, 2003; 124(6): 2098 - 2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle Haemodynamic evaluation of pulmonary hypertension Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Blankfield Clinical Correlates of Pulmonary Artery Systolic Pressure Circulation, August 13, 2002; 106 (7): e34 - e34. [Full Text] [PDF] |
||||
![]() |
R. V. Milani, C. J. Lavie, A. Rubiano, B. M. McQuillan, M. H. Picard, M. Leavitt, and A. E. Weyman Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects * Response Circulation, July 30, 2002; 106 (5): e19 - e19. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |